These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 35890393)
1. Tuning Design Parameters of ICAM-1-Targeted 3DNA Nanocarriers to Optimize Pulmonary Targeting Depending on Drug Type. Roki N; Solomon M; Bowers J; Getts L; Getts RC; Muro S Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890393 [TBL] [Abstract][Full Text] [Related]
2. Unprecedently high targeting specificity toward lung ICAM-1 using 3DNA nanocarriers. Roki N; Tsinas Z; Solomon M; Bowers J; Getts RC; Muro S J Control Release; 2019 Jul; 305():41-49. PubMed ID: 31100312 [TBL] [Abstract][Full Text] [Related]
3. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. Calderon AJ; Bhowmick T; Leferovich J; Burman B; Pichette B; Muzykantov V; Eckmann DM; Muro S J Control Release; 2011 Feb; 150(1):37-44. PubMed ID: 21047540 [TBL] [Abstract][Full Text] [Related]
4. B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model. Merlo LM; Bowers J; Stefanoni T; Getts R; Mandik-Nayak L Clin Pathol; 2020; 13():2632010X20951812. PubMed ID: 32924009 [TBL] [Abstract][Full Text] [Related]
5. Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers. Hsu J; Bhowmick T; Burks SR; Kao JP; Muro S J Biomed Nanotechnol; 2014 Feb; 10(2):345-54. PubMed ID: 24738342 [TBL] [Abstract][Full Text] [Related]
6. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Papademetriou IT; Garnacho C; Schuchman EH; Muro S Biomaterials; 2013 Apr; 34(13):3459-66. PubMed ID: 23398883 [TBL] [Abstract][Full Text] [Related]
8. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice. Garnacho C; Dhami R; Solomon M; Schuchman EH; Muro S Mol Ther; 2017 Jul; 25(7):1686-1696. PubMed ID: 28606376 [TBL] [Abstract][Full Text] [Related]
9. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581 [TBL] [Abstract][Full Text] [Related]
11. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers. Hsu J; Hoenicka J; Muro S Pharm Res; 2015 Apr; 32(4):1264-78. PubMed ID: 25319100 [TBL] [Abstract][Full Text] [Related]
12. Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice. Mane V; Muro S Int J Nanomedicine; 2012; 7():4223-37. PubMed ID: 22915850 [TBL] [Abstract][Full Text] [Related]
13. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes. Papademetriou I; Tsinas Z; Hsu J; Muro S J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603 [TBL] [Abstract][Full Text] [Related]
14. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth. Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342 [TBL] [Abstract][Full Text] [Related]
15. A method to improve quantitative radiotracing-based analysis of the in vivo biodistribution of drug carriers. Roki N; Solomon M; Casta L; Bowers J; Getts RC; Muro S Bioeng Transl Med; 2021 May; 6(2):e10208. PubMed ID: 34027094 [TBL] [Abstract][Full Text] [Related]
17. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Hsu J; Northrup L; Bhowmick T; Muro S Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578 [TBL] [Abstract][Full Text] [Related]
18. Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy. Li SJ; Wang XJ; Hu JB; Kang XQ; Chen L; Xu XL; Ying XY; Jiang SP; Du YZ Drug Deliv; 2017 Nov; 24(1):402-413. PubMed ID: 28165814 [TBL] [Abstract][Full Text] [Related]
19. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213 [TBL] [Abstract][Full Text] [Related]
20. Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy. Li S; Chen L; Wang G; Xu L; Hou S; Chen Z; Xu X; Wang X; Liu F; Du YZ J Nanobiotechnology; 2018 Dec; 16(1):105. PubMed ID: 30594254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]